Molycorp (MCP): JP Morgan moves Molycorp to Neutral from Overweight. Its price objective is $36. Zimmer Holdings (ZMH): The stock gets downgraded to Hold from Buy with a $54 target at Jefferies.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report ZIMMER HOLDINGS (ZMH): Free Stock Analysis Report
The company was added to the idea pipeline as Morningstar rates it a 5-star wide moat company. ZMH’s stock is currently trading at $51-52. 1- Business Performance Risk (=) and intrinsic returns (=) LTM: 11.8%, ROE has been constantly …
ZMH) from Buy to Hold. The analyst expects uncertainty regarding the company's performance to persist for the next several quarters, which would keep the stock range bound, at best. Zimmer Holdings announced on Wednesday that it …
Zimmer Holdings (NYSE: ZMH) has agreed with the European Commission (the "EC ... Zimmer will acquire Biomet in a cash and stock transaction valued at approximately $13.35 billion, including the assumption of net debt.
Zimmer Holdings Inc. (ZMH) is scheduled to report its third-quarter 2014 results ... show that Zimmer is likely to beat earnings this quarter. That is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1, 2 or …
In Thursday's regular trading session, ZMH is currently trading at $52.80, down $0.17 or 0.32% on a volume of 2.98 million shares. In the past 52 weeks, the stock has traded in a range of $41.79-$64.77.
Company Ticker Return Value (Millions) GENERAL MOTORS CO GM -1.1% 70 COVIDIEN PLC COV 11.1% 68 DIRECTV GROUP INC DTV 8.9% 67 MARKET VECTORS GOLD MINERS GDX -9.3% 46 ZIMMER HOLDINGS INC ZMH 12.9% …
Goldman Sachs is out with a research report this morning, where it upgraded shares of Zimmer Holdings Inc. (NYSE: ZMH) to Buy, from Neutral; it has a $75.00 price target on the stock. The GS analysts said, “We upgrade ZMH to Buy from …
Zimmer Holdings (NYSE: ZMH) announced that it has proposed a remedy package to ... Zimmer will acquire Biomet in a cash and stock transaction valued at approximately $13.35 billion, including the assumption of net debt.